Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluated Vanrafia against a placebo in individuals with IgA nephropathy who face the risk of worsening kidney function.

Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function decline in adults with immunoglobulin A nephropathy (IgAN). The ...

Google Slides tutorial covers setup and core tools; access via workspace.google.com with no install, presentations publish cleanly online.

SEOUL, South Korea, February 13, 2026--(BUSINESS WIRE)--Align Partners Capital Management Inc. ("Align Partners"), a shareholder of Gabia, Inc. ("Gabia" or the "Company"), has submitted formal ...

Access detailed historical stock prices, including daily closing prices, for ALHC. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

The Securities and Exchange Commission of Pakistan (SECP) has approved revisions to the Shariah screening criteria and methodology for the PSX-KMI All ...